Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I dose escalation trial of combination of GRANITE-001 with systemic Opdivo and Yervoy

Trial Profile

A Phase I dose escalation trial of combination of GRANITE-001 with systemic Opdivo and Yervoy

Planning
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs GRANITE 001 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jul 2018 New trial record
    • 19 Jul 2018 This trial is expected to start before the end of 2018 and is being conducted under a collaboration agreement between Bristol-Myers Squibb Company and Gritstone Oncology, according to a Gritstone Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top